What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?


Created by

 CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology

Associate Head, Division of Cardiology St. Michael’s Hospital